Colgate-Palmolive
CL · What the business does, what can go wrong, and how options sellers approach it
What it does
Colgate-Palmolive makes everyday consumer products. Its best-known business is oral care, including toothpaste and toothbrushes. It also sells personal care items such as soap and deodorant, plus home care products like dish soap.
Hill's, its pet nutrition business, sells largely through veterinarians and specialty pet retailers. Most company revenue comes from outside the United States.
How it makes money
The company sells branded products through supermarkets, mass retailers, pharmacies, e-commerce and, for Hill's, veterinary clinics and pet stores. Profit depends on pricing, product mix and the cost of raw materials, packaging and freight. It spends heavily on advertising and on dentist and veterinarian relationships.
Why investors own it
Many investors see it as a defensive consumer staples holding, since people buy toothpaste and pet food in most economic conditions. Its long dividend record draws income-focused investors. Some investors also value its emerging-market exposure and the Hill's pet nutrition business.
What can go wrong
- Raw material, packaging and freight costs can squeeze margins if prices cannot rise in step.
- A strong U.S. dollar reduces the value of foreign sales, and some emerging-market currencies can be volatile.
- Retailer private-label products and rival brands compete for shelf space and price-sensitive shoppers.
- Price increases can reduce volumes if consumers trade down.
- Pet food faces recall risk and changing consumer preferences.
What to watch
- Organic sales growth, split into volume and pricing
- Gross margin trends
- Results in emerging markets
- Hill's growth versus oral care
- Foreign exchange effects on reported results
- Advertising spending levels
- Dividend announcements and payout coverage
Options income angle
Options on CL are generally liquid, with reasonable activity in near-dated and monthly expirations, though spreads can be wider on strikes far from the current price. Implied volatility tends to be low compared with the broader market because the business is stable. It usually rises ahead of quarterly earnings and when input costs, currency swings or guidance are in focus.
One caution for premium sellers: a sharp drop after a disappointing earnings report can lead to losses on a short put or leave a covered call holder with a stock position worth less than expected.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 23, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Colgate-Palmolive grew 2025 net sales 1.4% to $20,382 million, but GAAP operating profit (profit under standard accounting rules) fell 23% to $3,306 million. The main cause was a non-cash write-down tied to the skin health business, mainly Filorga, which the filing links to weak performance in China. Excluding one-time items, operating profit was roughly flat, and management expects category softness to continue into 2026.
How the business did
- Sales: Net sales were $20,382 million, with price increases of 2.1% offset by volume declines of 0.4% and negative foreign exchange of 0.3%. Organic sales, which exclude currency, acquisitions and divestments, rose 1.4%.
- Profit: Diluted earnings per share were $2.63, down from $3.51. Excluding unusual items, they were $3.69 versus $3.60. Gross margin slipped to 60.1% from 60.5%, as higher raw and packaging costs (420 bps, or basis points, hundredths of a percentage point) outweighed savings (260 bps).
- Segments: Europe net sales rose 6.9% to $2,962 million. Hill's Pet Nutrition net sales rose 2.9% to $4,613 million, with operating profit up 10%. North America net sales fell 1.6%. Asia Pacific organic sales fell 1.0%, led lower by Greater China and India.
- Cash and capital return: Operating cash flow was $4,198 million. The company paid $1,823 million in dividends and spent $1,210 million on share repurchases. Total debt was $7,988 million.
- Unusual items: The skin health impairment was $919 million pretax. A $65 million charge came from a retirement plan lawsuit.
Risks specific to this company
- International exposure: About two-thirds of net sales come from outside the United States, and the filing singles out hyperinflationary Argentina, Nigeria and Türkiye. Eurasia was approximately 1% of net sales, and the company faces difficulty moving cash out of Russia.
- Tariffs and trade: The filing says tariffs and trade disputes, including the United States-Mexico-Canada Agreement renegotiation, have raised costs and unsettled consumers. Mitigation efforts could still leave a material effect.
- Powerful retailers: The company is increasingly dependent on key retailers with greater bargaining strength. They have demanded higher discounts and fees, and private label products compete on price.
- Litigation: The filing calls the impact of talc-related litigation highly uncertain. Separately, an adverse appeals ruling in a retirement plan lawsuit led to the $65 million charge.
- Skin health: After the impairment, goodwill for the skin health unit fell to $51 million. The Filorga trademark and customer relationships were written down to an immaterial amount.
- Tax dispute: The IRS disputes how income from an international operation is taxed. Tax plus interest for 2010 through 2018 is estimated at approximately $165 million. The company calls the assessment without merit and has not included it in its uncertain tax positions.
What management is watching
- 2026 demand: Management expects the softness seen across categories in 2025 to continue into 2026. It also expects some shoppers to trade down to private label or lower-priced items.
- Cost program: The Strategic Growth and Productivity Program, approved July 31, 2025, is estimated to cost between $200 and $300 million in pretax charges, with substantially all incurred by December 31, 2028. Charges so far are $13 million. Management also relies on its funding-the-growth cost-saving initiatives.
- 2030 strategy: Priorities include brand reach, science-based innovation, omni-channel demand generation (selling across stores, online and social media), and data and AI capabilities.
- Spending: Capital expenditures for 2026 are expected to be approximately 3.0% of net sales. Contributions to U.S. postretirement plans are expected to be $99 million.
- Measures it points to: These include organic sales growth, gross margin, operating profit and earnings per share on GAAP and non-GAAP bases, market share, and free cash flow. Global toothpaste share was 41.3%, down 0.4 share points.
Follow CL in Kortex
The Kortex app shows CL's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.